Siemens Healthineers and Novo join forces to advance care for people living with MASLD and MASHSeptember 22, 2026
Galimedix establishes Scientific Advisory Board for Alzheimer’s disease to guide development of novel oral drug candidate, GAL-101September 22, 2026
General Galimedix establishes Scientific Advisory Board for Alzheimer’s disease to guide development of novel oral drug candidate, GAL-101By Healthcare Propulsion StaffSeptember 22, 20260 Galimedix Therapeutics, Inc., a Phase 2 clinical-stage biotechnology company developing novel oral and topical neuroprotective therapies with the potential to…
